Azitra reports that the FDA has granted Rare Pediatric Disease Designation to ATR-12 for the treatment of Netherton syndrome, a chronic genetic skin disease that can be life threatening.
“Currently available treatments for NS have limited efficacy and can cause serious side effects; we are hopeful that ATR-12 will offer a new treatment option to patients suffering from this life-threatening disorder,” said Richard Andrews, President and CEO of Azitra.